Belluscura Share Discussion Threads

[dr biotech] 06/10/2023 06:29

There’s some right old guff in that article, not least the maths. What’s 9% of £10k? £450 according to him..

[hedgehog 100] 05/10/2023 16:18

Thanks for posting that helpful article, Mr. Oz.

From the article:-

"The only risk to this 9% upside is the deal falls through and then you're stuck with a holding without a purpose."



In my opinion, there's little chance of the deal falling through, because it isn't reliant upon raising any more funds.

And I can't really see that BELL would fail due diligence either. Though in theory, if it did, TMTA shares would likely hold up better than BELL, because of TMTA's cash underpinning.

In addition, TMTA would find another deal, possibly at an even higher premium.

It looks to me that BELL are getting TMTA relatively cheaply, as the percentage premium over TMTA's cash isn't high for a RTO-type deal.

I think that TMTA have probably agreed to relatively generous terms because they think that BELL is a particularly good opportunity.


And going back to Stuffee's point about shell investors selling after a deal for a profit.

The polar opposite can also happen, i.e. shell investors actually increasing their holdings after a takeover, if they like the new company, 'averaging up' their investment cost.

The enlarged market cap. will be far higher (by multiples) than the shell, so investors can buy far more without owning too high a percentage of one company.

And they will also have certainty about the business they're owning, whereas with a shell they can't be certain in advance of that.

[mr.oz] 05/10/2023 08:57

Good reading imv

[hedgehog 100] 04/10/2023 20:18

Thanks Stuffee.

Remember that as TMTA's IPO was at 20p (about two years ago), the vast majority of TMTA shares won't currently be showing any profit yet.

The TMTA share price fell on pretty low volume, so there's been little TMTA buying below the IPO price.

Also, don't underestimate the patience of shell investors - they must be some of the most patient investors out there.
Because you get long periods - sometimes even years - when seemingly nothing seems to be happening.


11/10/2021 08:01 UK Regulatory (RNS & others) TMT Acquisition PLC Admission and First Day of Dealings LSE:TMTA Tmt Acquisition Plc

" ... Prior to Admission, the Company had in issue 2,500,000 Ordinary Shares and at Admission issued a further 25,000,000 Ordinary Shares at a placing price of 20p per Ordinary Share, raising gross proceeds of GBP5 million. ..."

[stuffee] 04/10/2023 19:57

Hedgehog

You may well be right that former TMT sharehoders will follow their investment and retain their Bell shares. I took the cautious view, prior to much research on TMT, that most shell investors prefer to travel rather than arrive and will cash in for quick profit, once a deal concludes.

I was impressed by your comprehensive posts on TMT and your enthusiasm for Bell. Hope other TMT investors read your posts and the Bell price doesn't suffer from too much short term selling.

Encouraging that some former high quality TMT directors joining Bell board,

[hedgehog 100] 04/10/2023 16:21

It's intended that TMTA non-exec. director Jonathan Satchell will join BELL's board, along with TMTA's newest director Paul Tuson.

"Jonathan Satchell
Non-Executive Director

Jonathan Satchell is Chief Executive of Learning Technologies Group plc (“LTG”). LTG is listed on the AIM market of London Stock Exchange (LTG.L) and headquartered in London. LTG is at the forefront of innovation and best-practice in the learning and talent software sector, and has received numerous awards for its achievements both corporately and for clients.

Jonathan has worked in the training industry since 1992. In 1997 he acquired EBC, which he transformed from a training video provider to a bespoke e-learning company. The company was sold to Futuremedia in 2006. He became interim MD of Epic in 2007 and the following year he acquired the Company with LTG’s chairman. He oversaw the transformation of Epic from a custom content e-learning company to the global, fast growing, full service digital learning and talent management company that LTG has become. Jonathan is also non-executive director of Zappar, the world’s leading augmented reality platform and creative studio."




LTG's current market cap. is £523 million, at 66.1p/share.

And LTG 40-bagged from its RTO price of 5.88p/share to its high of about 236p in 2021.


Learning Technologies Group (LTG):-

[hedgehog 100] 04/10/2023 15:40

Closing s.p.s today:-
BELL 35p (32p - 38p).
TMTA 19.5p (19p - 20p).

On the basis that TMTA shareholders will receive 15 BELL shares for every 22 TMTA shares, the current TMTA offer price of 20p/share equates to a BELL offer price of 29.33p/share, i.e. 22.82% less than the current BELL offer price of 38p.

So TMTA is potentially a significantly cheaper way into BELL at the moment than buying BELL shares directly.


Stuffee,

Why don't you feel that TMTA shareholders will be natural shareholders for BELL?

The whole point of buying a shell like TMTA is that it's potentially a cheaper route into a non-shell company; shell investors neither expect nor want it to remain a shell forever.

And TMTA was set up specifically to invest into a tech company like BELL:-

"TMT Acquisition was incorporated in March 2021. The Company has been formed to pursue opportunities to acquire businesses in the technology, media and telecom sector (“TMT sector”)."

[stuffee] 04/10/2023 10:37

Dr B

I agree, the statement made in May concerning forecast sales of 4,000 to 12,000 units in current year may prove to have been irresponsibility optimistsic (apologies in advance if I'm wrong). It is typical of many such wild financial statements over last two years by Bell (the classic being when the now former CFO, during broacast interview, stated its temporary funding shortfall would be bridged by invoice financing when Bell didn't have any meaningful sales to invoice!) Lets hope the former CFO's early bath will lead to more responsible statements and his successor follows policy of under promising and over delivering, in order to generate decent market respect and rating.

I though the TMT acquisition quite neat, securing £4.7m of cash without tapping existing shareholders. Although the transaction is slightly dilutive, being equivalent of issuing new share at 25p, it probably removes short term funding concerns. I guess Bell has been vulnerable to shorting over last few months when some new share issue appeared inevitable. I doubt many former TMT shareholders will be natural holders of Bell, so some short term barrier preventing significant share price rise inevitable for a few months.

I still believe in Bell, with its exciting product and potential. With its cash raised, risk removed and hopefully more experienced financial management, I feel the medium term future looks very promising.

[dr biotech] 03/10/2023 16:52

So a placing of sorts at a similar price to the last one. I guess that gives a bit more stability. A positive.

I've looked at the last placing statement in May -they said

"Trading in 2023 is still expected to see progress on 2022, albeit with a significant second half weighting. The Company currently expects to sell between 4,000 and 12,000 units in the current year, of which the higher margin DISCOV-R will represent between 30 to 35 per cent"

Given sales in the first 6 month were $400k - which equates to approx 300 units that means they think they will sell 3700-11700 in the H2. Which we are halfway through. Anyone else think this is unlikely? So H2 will be 10-40x better than H1.

[brummy_git] 03/10/2023 14:47

3 positive announcements today from leading portable oxygen concentrator firm Belluscura

All the details here.
HTPPS://www.linkedin.com/posts/paul-hill-a5994116_bell-bell-tmta-activity-7114982755163090946-hJA9?utm_source=share&utm_medium=member_desktop

[jaknife] 03/10/2023 13:20

owenski,


They're issuing 18,750,000 shares to acquire a cash shell with unaudited cash of £4,735,575 but there are some liabilities so it's only worth £4,717,188.

So £4,717,188 / 18,750,000 = 25.2p per share

JakNife

[owenski] 03/10/2023 13:16

Good for TMT holders I guess, they get a premium.

I hope I've read that correctly, BELL are printing off 6m of shares to buy 4 and a bit million in ready cash.

Plus the other CLN's being issued.

Well I guess hopefully they're fully funded now, and if they do manage to actually launch and sell before year end and the take up is as the say, then BELL might finally be worth holding.

[babbler] 03/10/2023 12:54

Interesting news...

[dr biotech] 26/9/2023 08:52

They have sold one demo price unit in Hong Kong, woohoo release an RNS.

I’ve just noticed one of their “awards” is actually an advertorial in gizmodo, where they “review” five different concentrators and give them all a recommendation.

hxxps://gizmodo.com/advisor/portable-oxygen-concentrators/best-portable-oxygen-concentrators/

I don’t think the battery life is long enough for travel. Certainly not if you are hoping to catch a train over here.

And don’t forget the Discov-r is behind schedule, the the January RNS “ The first DISCOV-R(TM) POCs expect to be launched for pre-market evaluation in Q1 2023, with full commercialisation anticipated in Q2”.

Value this company on what they actually sell, not what they say.

[adorling] 26/9/2023 06:50

Great news!

[brummy_git] 26/9/2023 06:28

New regulatory approval granted in Hong Kong for Belluscura's X-PLOR portable oxygen concentrator.

Find out all the details here.

[buywell3] 26/9/2023 06:24

RNS today and decent progress in a short timescale IMO -- less than a month ago

Belluscura Enters Exclusive License Agreement

Belluscura PLC
30th August 2023

InnoMax, headquartered in Shenzhen, China, has acquired the exclusive right to manufacture and distribute Belluscura's award winning X-PLOR® portable oxygen concentrator in China, Hong Kong, Macau and Singapore ("the Territories"). In addition to the X-PLOR, the agreement will also include the DISCOV-R™, the Company's next generation, ambulatory dual flow portable oxygen concentrator, when registration is received in the Territories for both devices.

-----------------------------------------------------





Belluscura Receives Approval in Hong Kong

Belluscura PLC
26th September 2023

Belluscura has already received its first purchase order from a Hong Kong distributor. Hong Kong is part of the licensed territory in its Exclusive License Agreement signed last month with Innomax Medical Device Technologies.



The Company is also pleased to announce the successful completion of the DISCOV-R™ portable oxygen concentrator patient usability study with all participants providing favorable feedback on the device. Initial production of the DISCOV-R™ will commence this week. Full-scale production is being planned in conjunction with Innomax in response to the significant preliminary demand already received by the Company.





Bob Rauker, Chief Executive Officer, Belluscura plc, commented:

"We are very excited to receive the approval and begin sales in Hong Kong.

I am very pleased with our operations, quality control and sales teams receiving approval ahead of schedule.

Hong Kong is phase one of our joint expansion with Innomax into Asia."



buywell adds:

RNS's for --- China, Macau, Singapore to soon follow


dyor

[buywell3] 23/9/2023 07:07

wrt the above Long Covid research findings regarding lung damage on the BBC today --- namely

The study, published in Lancet Respiratory Medicine, looked at 259 patients who fell so ill with the virus that they were admitted to hospital.

Five months after they were discharged, MRI scans of their major organs showed some significant differences when compared to a group of 52 people who had never had Covid.

The biggest impact was seen on the lungs, where the scans were 14 times more likely to show abnormalities.







-------------------- India and Long Covid ---------------------


Many millions of people have caught Covid-19 in India


It should follow that Long Covid issues involving Lung Damage will now be showing themselves

Courtesy of the Weather Channel

-----------------------------------

Even After Recovery From COVID-19, Patients Continue to Struggle with Respiratory Complications, Claim Doctors

By IANS 2 days ago TWC India

Although the COVID pandemic has abated, survivors of the virus continue to experience a range of post-acute respiratory complications, according to doctors.

Dr. Manisha Mendiratta, Head of Department and Senior Consultant in Pulmonology at Sarvodaya Hospital, noted that many individuals still grapple with persistent shortness of breath and cough, even months after their initial infection.

Additionally, some have developed conditions such as pulmonary fibrosis, a progressive and debilitating disease. Bronchiectasis, where the airways become damaged and widened, is also emerging as a significant issue.

These lung-related complications necessitate long-term monitoring and management.

Dr. Mendiratta emphasised the surge in post-acute respiratory issues in COVID-19 patients, which were relatively rare before the pandemic.

Conditions like post-acute sequelae of SARS-CoV-2 infection (PASC) can lead to interstitial lung abnormalities, pulmonary fibrosis, or bronchiectasis, seriously impacting a patient's quality of life and requiring ongoing medical management.

She further explained that COVID-19 can damage the lungs in various ways, even in mild cases. The virus can cause inflammation in the airways and lung tissue, leading to scarring or fibrosis, reduced lung function, and persistent breathing difficulties.

Some individuals may experience chronic coughing, shortness of breath, or a decreased ability to exercise.

While there is ongoing research and clinical trials to better understand and treat long COVID pulmonary complications, there is no definitive medical solution at this time.

Patients often require a multi-disciplinary approach, including pulmonary rehabilitation, medications to manage symptoms and lifestyle modifications. The prognosis varies depending on the severity of complications, and some patients may need to manage these issues for an extended period or even lifelong.

Dr. Mendiratta stressed the importance of ongoing research to improve understanding and develop more effective treatments for long COVID pulmonary complications.



dyor

[buywell3] 23/9/2023 06:32

Lungs that have been left damaged and scarred by Covid-19 will NOT function as well as normal lungs

This will mean that blood/oxygen ratios will NOT be normal

The most common symptom of people with Long Covid is ' breathing difficulties' as well as tiredness and fatigue

ALL associated with poor lung function

Home oxygen therapy for such Long Covid sufferers will IMO give many some sort of normality and would enable many to walk around using a portable oxygen concentrator whilst being monitored for their SO2 levels and other data --- that NOMAD can provide

The provision of full time carers for such Long Covid sufferers could be avoided by the use of home oxygen therapy with lightweight portable oxygen concentrators

The provision of carers for 2,000,000 people suffering from Long Covid will IMO cost much much more .












Long Covid: MRI scans reveal new clues to symptoms

Published
6 hours ago


People living with long Covid after being admitted to hospital are more likely to show some damage to major organs, according to a new study.

MRI scans revealed patients were three times more likely to have some abnormalities in multiple organs such as the lungs, brain and kidneys.

Researchers believe there is a link with the severity of the illness.

It is hoped the UK study will help in the development of more effective treatments for long Covid.

The study, published in Lancet Respiratory Medicine, looked at 259 patients who fell so ill with the virus that they were admitted to hospital.

Five months after they were discharged, MRI scans of their major organs showed some significant differences when compared to a group of 52 people who had never had Covid.

The biggest impact was seen on the lungs, where the scans were 14 times more likely to show abnormalities.







How many people in the UK now have Long Covid ?




dyor


yesterday's trades


Sep 22, 2023 16:07:03 37.75p 50,000 £18,875.00
Sep 22, 2023 16:35:02 39.00p 3 £1.17
Sep 22, 2023 16:35:02 39.00p 15 £5.85
Sep 22, 2023 16:35:02 34.50p 9,000 £3,105.00
Sep 22, 2023 16:14:59 36.25p 6,400 £2,319.87
Sep 22, 2023 14:23:09 34.00p 56 £19.04
Sep 22, 2023 10:32:23 35.89p 5,000 £1,794.50
Sep 22, 2023 10:14:54 34.25p 2,144 £734.32
Sep 22, 2023 08:16:35 36.25p 4,126 £1,495.68
Sep 22, 2023 08:14:32 34.00p 85 £28.90
Sep 22, 2023 08:14:25 35.00p 5,000 £1,750.00
Sep 22, 2023 08:04:29 35.00p 5,000 £1,750.00
Sep 21, 2023 16:02:20 36.48p 2,708 £987.88

[buywell3] 21/9/2023 05:44

Back to Long Covid

buywell remains convinced that at some point oxygen therapy given perhaps at a low level , will become necessary for many Long Covid sufferers that present low blood oxygen saturation levels


Very recently this study was published

Review Article
Published: 04th September 2023
COVID-19

SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)




For a simplified explanation read


Sept 7th 2023

Scientists detail current evidence that Long COVID is caused by persistent SARS-CoV-2 viral reservoirs

"A new and important review of the persistence of SARS-CoV-2 in tissue as a reservoir, a key underpinning of Long Covid",
The paper reviews evidence showing that some patients with Long COVID - and more surprisingly, some with no symptoms - do not fully clear the SARS-CoV-2 virus after initial infection. Instead, the virus can persist in patient organ tissue as a "reservoir" - such as in the gut or lungs.
These reservoirs could be one of the primary drivers of the Long COVID disease process.
For example, coauthors Michael Peluso MD and team at UCSF recently found SARS-CoV-2 in Long COVID colon tissue up to 676 days following initial infection.


Publication of the paper makes it clear that top researchers in the Long COVID space are taking SARS-CoV-2 persistence seriously.
"A new and important review of the persistence of SARS-CoV-2 in tissue as a reservoir, a key underpinning of Long Covid", writes Eric Topol MD, director of the Scripps Research Translational Institute on Twitter/X.
Indeed, as the paper emphasizes, the study of SARS-CoV-2 reservoir in Long COVID may inform the identification of disease mechanisms, biomarkers, and therapeutics for other chronic conditions now being tied to persistent viral infection including ME/CFS, Alzheimer's disease, and multiple sclerosis.








buywell notes that Long Covid is also being linked with Alzheimer's and plaques in the brain of those that have become Long Covid sufferers

Clinical studies have shown that oxygen therapy significantly improved cognitive function and brain metabolism, and positively regulated the activity of local neurons in brain regions.

Apr 25th 2022

The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review



Increasing evidence also suggests that oxygen therapy may improve many pathological aspects of AD including amyloid-beta metabolism, tau phosphorylation, neuroinflammation, neuronal apoptosis, oxidative stress, neurotrophic factors, mitochondrial function, cerebral blood volume, and protein synthesis.



--------------------------------------------------------------------



In the UK the NHS state


Who can benefit from home oxygen therapy?

Home oxygen therapy can be useful for people who do not have enough oxygen in their blood.

It can help with conditions such as:

chronic obstructive pulmonary disease (COPD)
pulmonary fibrosis
heart failure
severe long-term asthma
pulmonary hypertension
cystic fibrosis
breathing problems caused by a combination of being obese and having an underlying condition

[tanners] 19/9/2023 15:03

Great post Masarap......and whilst I have a great deal of respect for Jaknife, who over the years has called out a number of scams, the same comment can be applied to him too.

Optibiotix is another example......turnover of a corner shop, missed sales targets and endless losses etc but not a peep from Jaknife on the various threads...of course the fact that TW has been a long term supporter of Opti is a mere coincidence I'm sure!

[bill216] 19/9/2023 07:27

Thanks...and with confirmed orders is trade finance a possibility rather than equity funding for production ?